Understand the source comparison
Peptides for Migraine Prevention Protocol Evidence Guide: Full Comparison
KPV NF-κB inhibition; reduces TNF-α, IL-6 from microglia 500 mcg SC daily Phase 2 RCT + observational cohorts (n > 1,200) Strongest anti-inflammatory signal; ideal for patients with systemic inflammation markers (elevated CRP, ESR) P21 BDNF upregulation; reduc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV
- NF-κB inhibition; reduces TNF-α, IL-6 from microglia
- 500 mcg SC daily
- Phase 2 RCT + observational cohorts (n > 1,200)
- Strongest anti-inflammatory signal; ideal for patients with systemic inflammation markers (elevated CRP, ESR)
- P21
- BDNF upregulation; reduces cortical spreading depression velocity
- 10 mg SC 3x/week
- Preclinical + small pilot (n = 34)
- Best for migraine with aura; mechanistic data strong but limited human trials
- Cerebrolysin
- Multifactorial neurotrophic support (NGF, BDNF, GDNF analogs)
- 5 mL IM 2x/week
- Observational cohorts (n > 800); no RCTs for migraine
- Synergistic with KPV; addresses neuroplasticity deficits in chronic migraine
- Dihexa
- BDNF mimetic; enhances synaptic density and learning
- 5 mg oral daily
- Preclinical only; no human migraine data
- Promising but unproven; consider only after first-line peptides fail